Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04881617 · ClinicalTrials.gov registry record · NA

Treatment for Speech and Language in Primary Progressive Aphasia

A NA study of Aphasia and Primary Progressive Aphasia, sponsored by University of Texas at Austin.

Active
Registry status
NA
Development phase
60
Enrollment target
2
Study locations

NCT04881617: Active NA study of Aphasia and Primary Progressive Aphasia, sponsored by University of Texas at Austin.

NCT04881617 is a NA study of Aphasia and Primary Progressive Aphasia that is active but no longer recruiting, run by University of Texas at Austin. The registered enrollment target is 60 participants, below the 82-participant average among 42 other Aphasia trials with a reported enrollment target (27% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04881617, a NA study of Aphasia and Primary Progressive Aphasia, is active but no longer recruiting, sponsored by University of Texas at Austin.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain. PPA is a devastating condition affecting adults as young as their 40's or 50's, depriving them of the ability to communicate and function in society. There has been significant progress in discovering the neurobiological mechanisms that underlie PPA and in identifying its clinical phenotypes. With these advances, we are poised to investigate behavioral treatments that are grounded in modern cognitive and neuroanatomical concepts. Research documenting the efficacy of speech-language treatment for PPA is emerging, but limited. Systematic research is needed to establish best clinical practices in this unique patient population for whom pharmacological treatment remains elusive. The long-term objectives of this project are to provide evidence-based treatment methods addressing the speech and language deficits in PPA and to determine the neural predictors of responsiveness to intervention. The study has three main goals that build on the findings of our previous work: 1) to examine the utility of treatments designed to facilitate significant, generalized and lasting improvement of speech-language function in PPA, 2) to determine whether treatment alters the trajectory of decline in PPA by comparing performance on primary outcome measures in treated versus untreated participants after a one-year interval, and 3) to identify imaging predictors (gray matter, white matter, and functional connectivity measures) of responsiveness to behavioral intervention in individuals with PPA. In order to accomplish these aims, we will enroll 60 individuals with PPA, who will undergo a comprehensive multidisciplinary evaluation and neuroimaging. Subsequently, participants will be enrolled in treatment designed to promote lasting and generalized improvement of communicative fun

Primary Outcome

Change in percent correctly named trained/untrained pictures

Conditions Studied

Aphasia Primary Progressive Aphasia Logopenic Progressive Aphasia Semantic Dementia Nonfluent Aphasia, Progressive Semantic Memory Disorder Aphasia, Progressive

Interventions

  • BEHAVIORAL Video-Implemented Script Training for Aphasia (VISTA)
  • BEHAVIORAL Lexical Retrieval Training (LRT)

Study Locations (2)

California

  • University of California San Francisco - San Francisco

Texas

  • University of Texas - Austin

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2017-07-01
Est. Completion 2025-12-30
Phase NA
University of Texas at Austin

257 total trials

What the registry record for NCT04881617 still lists

NCT04881617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 82-participant average among 42 other Aphasia trials with a reported enrollment target (27% lower).

The record links to 7 conditions, with Aphasia appearing as the primary indexed condition, and to 2 interventions - of which Video-Implemented Script Training for Aphasia (VISTA) is the first listed.

NCT04881617 reports a single indexed study location in California, Texas.

Frequently Asked Questions

What is clinical trial NCT04881617 about?

NCT04881617 is a clinical study titled "Treatment for Speech and Language in Primary Progressive Aphasia". Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain. PPA is a devastating condition affecting adults as young as their 40's or 50's, dep...

What is the current status of trial NCT04881617?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2017-07-01. Estimated completion is 2025-12-30.

What conditions does trial NCT04881617 study?

This clinical trial studies the following conditions: Aphasia, Primary Progressive Aphasia, Logopenic Progressive Aphasia, Semantic Dementia, Nonfluent Aphasia, Progressive.

What interventions are being tested in trial NCT04881617?

The interventions under investigation include: Video-Implemented Script Training for Aphasia (VISTA) (BEHAVIORAL), Lexical Retrieval Training (LRT) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04881617?

This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04881617 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Aphasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04881617's enrollment target sits among peer trials

60 22nd of 42 higher than 21 of 42 other Aphasia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aphasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04881617, the US trial registry maintained by the National Library of Medicine. NCT04881617 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.